Cymbopogonol, a new triterpenoid from Cymbopogon citratus

Hanson, Svenja; Crawford, Malcolm; Koker, Moustapha E. S.; Menezes, Francis A.

doi:10.1016/s0031-9422(00)84411-8

Cited by 17 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemical composition. Essential oil (with geranial, neral and myrcene as the major constituents) ( Leclercq et al, 2000 ; Menut et al, 2000 ; Pino and Rosado, 2000 ; Sidibé et al, 2001 ; Ali et al, 2004 ; Kanko et al, 2004 ; Pérez et al, 2006 ; Rodriguez-Pérez et al, 2006 ; Brito et al, 2011 ; Silva et al, 2014 ; Diop et al, 2017 ; Soliman et al, 2017 ; Alam et al, 2018 ; Silva et al, 2018 ; BRASIL, 2019a ); triterpenes (e.g., cymbopogonol; cymbopogone) ( Hanson et al, 1976 ); flavonoids (e.g., luteolin, apigenin, kaempferol) ( Cheel et al, 2005 ; Orrego et al, 2009 ; Costa et al, 2015a ; Costa et al, 2015b ); phenolic acids (e.g., caffeic, chlorogenic, ferulic acids and derivatives) ( Tapia et al, 2007 ).…”

Section: Resultsmentioning

confidence: 99%

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

Background: Current recommendations for the self-management of SARS-Cov-2 disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case of high fever only. It is expected that many patients will add other symptomatic/adjuvant treatments, such as herbal medicines. Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally indicated for "respiratory diseases" within the current frame of the COVID-19 pandemic as an adjuvant treatment. Method: The plant selection was primarily based on species listed by the WHO and EMA, but some other herbal remedies were considered due to their widespread use in respiratory conditions. Preclinical and clinical data on their efficacy and safety were collected from authoritative sources. The target population were adults with early and mild flu symptoms without underlying conditions. These were evaluated according to a modified PrOACT-URL method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks balance of the treatments was classified as positive, promising, negative, and unknown. Results: A total of 39 herbal medicines were identified as very likely to appeal to the COVID-19 patient. According to our method, the benefits/risks assessment of the herbal medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea, Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we could not find compelling evidence to endorse the use of paracetamol and/or codeine. Conclusions: Our work suggests that several herbal medicines have safety margins superior to those of reference drugs and enough levels of evidence to start a clinical

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Bottini et al [40] isolated a novel bis-monoterpenoid named cymbodiacetal (22) from C. martinii. The triterpenoids cymbopogone (23) and cymbopogonol (24) (Figure 1) were also reported from the leaves of C. citratus [41].…”

Section: Non-volatile Terpenoidsmentioning

confidence: 85%

Cymbopogon Species; Ethnopharmacology, Phytochemistry and the Pharmacological Importance

et al. 2015

View full text Add to dashboard Cite

Abstract:Cymbopogon genus is a member of the family of Gramineae which are herbs known worldwide for their high essential oil content. They are widely distributed across all continents where they are used for various purposes. The commercial and medicinal uses of the various species of Cymbopogon are well documented. Ethnopharmacology evidence shows that they possess a wide array of properties that justifies their use for pest control, in cosmetics and as anti-inflammation agents. These plants may also hold promise as potent anti-tumor and chemopreventive drugs. The chemo-types from this genus have been used as biomarkers for their identification and classification. Pharmacological applications of Cymbopogon citratus are well exploited, though studies show that other species may also useful pharmaceutically. Hence this literature review intends to discuss these species and explore their potential economic importance.

show abstract

“…Isolated and identified new triterpenoids from leaf wax are cymbopogone and cymbopogonol [ Figure 2 ]. [ 30 ]…”

Section: Phytochemistrymentioning

confidence: 99%

Scientific basis for the therapeutic use of Cymbopogon citratus, stapf (Lemon grass)

Shah

Shri

Panchal

et al. 2011

J Adv Pharm Technol Res

369

189

View full text Add to dashboard Cite

Cymbopogon citratus, Stapf (Lemon grass) is a widely used herb in tropical countries, especially in Southeast Asia. The essential oil of the plant is used in aromatherapy. The compounds identified in Cymbopogon citratus are mainly terpenes, alcohols, ketones, aldehyde and esters. Some of the reported phytoconstituents are essential oils that contain Citral α, Citral β, Nerol Geraniol, Citronellal, Terpinolene, Geranyl acetate, Myrecene and Terpinol Methylheptenone. The plant also contains reported phytoconstituents such as flavonoids and phenolic compounds, which consist of luteolin, isoorientin 2’-O-rhamnoside, quercetin, kaempferol and apiginin. Studies indicate that Cymbopogon citratus possesses various pharmacological activities such as anti-amoebic, antibacterial, antidiarrheal, antifilarial, antifungal and anti-inflammatory properties. Various other effects like antimalarial, antimutagenicity, antimycobacterial, antioxidants, hypoglycemic and neurobehaviorial have also been studied. These results are very encouraging and indicate that this herb should be studied more extensively to confirm these results and reveal other potential therapeutic effects.

show abstract

Cymbopogonol, a new triterpenoid from Cymbopogon citratus

Cited by 17 publications

References 4 publications

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?

Cymbopogon Species; Ethnopharmacology, Phytochemistry and the Pharmacological Importance

Scientific basis for the therapeutic use of Cymbopogon citratus, stapf (Lemon grass)

Contact Info

Product

Resources

About